B
Beilei Liu
Researcher at University of Hong Kong
Publications - 20
Citations - 240
Beilei Liu is an academic researcher from University of Hong Kong. The author has contributed to research in topics: Cancer research & Medicine. The author has an hindex of 4, co-authored 6 publications receiving 52 citations. Previous affiliations of Beilei Liu include Li Ka Shing Faculty of Medicine, University of Hong Kong.
Papers
More filters
Journal ArticleDOI
Comprehensive single-cell sequencing reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of nasopharyngeal carcinoma.
Lanqi Gong,Lanqi Gong,Dora L.W. Kwong,Dora L.W. Kwong,Wei Dai,Wei Dai,P.M. Wu,Shan-Shan Li,Qian Yan,Qian Yan,Yu Zhang,Baifeng Zhang,Xiaona Fang,Li Liu,Min Luo,Beilei Liu,Larry Ka-Yue Chow,Qing-Yun Chen,Jinlin Huang,Victor Ho-Fun Lee,Victor Ho-Fun Lee,Ka-On Lam,Ka-On Lam,Anthony Wing Ip Lo,Zhiwei Chen,Yan Wang,Anne Wing-Mui Lee,Anne Wing-Mui Lee,Xin Yuan Guan,Xin Yuan Guan,Xin Yuan Guan +30 more
TL;DR: Wang et al. as mentioned in this paper applied single-cell RNA sequencing to 66,627 cells from 14 patients, integrated with clonotype identification on T and B cells. And they revealed the correlation between NPC-specific characteristics and progression-free survival.
Journal ArticleDOI
Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity.
Tu-Xiong Huang,Xiangyu Tan,Hui-Si Huang,Yuting Li,Beilei Liu,Kai-Sheng Liu,Xinchun Chen,Zhe Chen,Xin Yuan Guan,Chang Zou,Li Fu +10 more
TL;DR: Zhang et al. as discussed by the authors investigated the mechanism underlying CAFs-mediated tumour immune evasion and developed novel therapeutic strategies targeting CAFs for enhancing ICI efficacy in oesophageal squamous cell carcinoma and colorectal cancer.
Journal ArticleDOI
Cancer cell reprogramming: a promising therapy converting malignancy to benignity.
TL;DR: This review aims to discuss recent applications in cancer cell reprogramming, with a focus on the clinical significance and limitations of different reprogrammers approaches, while summarizing vital roles played by transcription factors, small molecules, microRNAs and exosomes during the reprograming process.
Journal ArticleDOI
C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism.
Yu Zhang,Qian Yan,Qian Yan,Lanqi Gong,Hang Xu,Beilei Liu,Xiaona Fang,Dandan Yu,Dandan Yu,Lei Li,Ting Wei,Ying Wang,CN Wong,Zhaojie Lyu,Ying Tang,Pak C. Sham,Xin Yuan Guan +16 more
TL;DR: In this paper, the authors investigated the role of the C-terminal truncated X protein (C-HBx) in hepatocellular carcinoma (HCC) development.
Journal ArticleDOI
PGC7 promotes tumor oncogenic dedifferentiation through remodeling DNA methylation pattern for key developmental transcription factors.
Qian Yan,Yu Zhang,Xiaona Fang,Beilei Liu,Tin Lok Wong,Lanqi Gong,Shan Liu,Dandan Yu,Ming Liu,Lingxi Jiang,Xia Wang,Ting Wei,Yongxu Jia,Lei Li,Liangzhan Sun,Ying Tang,Ning-Ning Zhou,Yunfei Yuan,Yan Li,Stephanie Ma,Xin Yuan Guan +20 more
TL;DR: In this article, the maternal factor PGC7 (also known as DPPA3, STELLA) was found closely associated with liver development and tumor differentiation in hepatocellular carcinoma (HCC).